Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Core Viewpoint - Zenas BioPharma's experimental drug has demonstrated effectiveness in reducing the risk of disease flare-ups in patients with a rare immune system-related condition in a late-stage study [1] Group 1 - The drug targets a condition that can lead to organ damage over time [1]